Filing Details
- Accession Number:
- 0001628280-24-052267
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-20 18:04:26
- Reporting Period:
- 2024-12-18
- Accepted Time:
- 2024-12-20 18:04:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 879407 | Arrowhead Pharmaceuticals Inc. | ARWR | Pharmaceutical Preparations (2834) | 460408024 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1423029 | Richard Christopher Anzalone | 177 E. Colorado Blvd Suite 700 Pasadena CA 91105 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-12-18 | 12,653 | $20.52 | 3,702,394 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-12-18 | 8,260 | $21.74 | 3,694,134 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-12-18 | 5,799 | $22.12 | 3,688,335 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-12-18 | 100,000 | $0.00 | 3,788,335 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Footnotes
- Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- Partial disposition of performance RSUs to satisfy tax withholding obligations. The performance RSUs were subject to a performance condition, which the Compensation Committee of the Company certified as achieved on December 17, 2024.
- The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $21.11, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
- The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.04, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.05 to $22.27, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- Represents shares underlying restricted stock units with a grant date 12/18/24, which will vest in four equal annual installments.
Billionaire Hedge Funds
